What's Happening?
Crown Bioscience, a global contract research organization, has opened a new model development center in Kannapolis, North Carolina. This facility will enhance the company's capabilities in delivering advanced preclinical oncology models, including patient-derived xenografts and organoids. The expansion aligns with Crown Bioscience's strategy to provide localized access to global scientific expertise and support the growing demand for innovative drug development models.
Why It's Important?
The opening of the new facility is a strategic move to strengthen Crown Bioscience's presence in the U.S. and support the evolving needs of the pharmaceutical and biotechnology industries. As precision medicine and regulatory frameworks advance, the demand for scalable and translatable models in drug development is increasing. This expansion positions Crown Bioscience as a key player in providing cutting-edge solutions for oncology research.
What's Next?
The Kannapolis site is expected to become fully operational in October, creating new opportunities for local talent and contributing to the regional economy. The facility will support Crown Bioscience's model platform portfolio and accelerate the adoption of 3D cell culture technologies. The company will continue to collaborate with its other facilities to enhance its service offerings and meet industry demands.
